Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.78 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.76 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.76 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.76 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.76 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL11534580 | 0.88 | CYP19A1 (0.81) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| SCHEMBL570342 | 0.87 | CYP11B1 (1.00) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| SCHEMBL4701021 | 0.83 | CYP19A1 (0.70) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| SCHEMBL4492287 | 0.83 | CYP19A1 (0.75) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL9853939 | 0.81 | CYP19A1 (0.73) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL12639833 | 0.81 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| SCHEMBL6302514 | 0.81 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| SCHEMBL10247505 | 0.81 | CYP19A1 (0.72) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL412748 | 0.80 | CYP19A1 (0.70) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 | |
| SCHEMBL1024261 | 0.80 | CYP11B1 (0.84) | CYP19A1CYP11B1CYP11B2CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | disclosed |
| EP-2121616-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | Campiani, Giuseppe (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008101891-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | QTRT1, QTRT2, IL4I1 | CYP19A1 3969/4885CYP11B1 2405/4885CYP11B2 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.